Clinical Trial Update: A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study of TC-510 from TCR2 Therapeutics in mesothelin-expressing cancers is active but not recruiting, spanning multiple indications including mesoth…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma
• Colorectal Cancer
• Mesothelioma
• Non-small Cell Lung Cancer
• Ovarian Cancer
• Pancreatic Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• TC-510

Snippet

Sponsor: TCR2 Therapeutics | Conditions: Mesothelioma, Mesotheliomas Pleural | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING